Teladoc Health (NYSE:TDOC) Releases FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -1.000–0.750 for the period, compared to the consensus estimate of -0.810. The company issued revenue guidance of $2.4 billion-$2.4 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q3 2026 guidance to -0.300–0.200 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TDOC shares. Bank of America lifted their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group cut their target price on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Citigroup raised their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teladoc Health presently has an average rating of “Hold” and a consensus target price of $7.50.

Teladoc Health Trading Down 29.2%

Shares of TDOC stock traded down $2.69 on Thursday, reaching $6.50. 20,913,586 shares of the stock were exchanged, compared to its average volume of 5,496,717. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1.17 billion, a P/E ratio of -6.71 and a beta of 2.10. The firm has a 50 day moving average of $8.21 and a two-hundred day moving average of $6.55. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. The company had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The firm’s revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, research analysts anticipate that Teladoc Health will post -0.92 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This represents a 9.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock worth $299,058 over the last 90 days. Company insiders own 0.70% of the company’s stock.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the $0.24 consensus estimate. Management also highlighted efficiency efforts, while operating cash flow totaled $64.7 million. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: Canaccord Genuity lowered its price target from $11 to $10 but retained a “buy” rating, implying substantial potential upside from recent levels. Benzinga analyst price target report
• Positive Sentiment: Unusually heavy call-option activity—15,650 contracts, about 30% above average—suggests some traders are positioning for a rebound, although options flows can be speculative and volatile.
• Neutral Sentiment: The second-quarter net loss was $38.9 million, or $0.21 per share, compared with a $0.19 loss a year earlier. However, first-half cost controls narrowed the net loss even as sales remained under pressure. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Negative Sentiment: Revenue fell 4% year over year to $606.9 million, missing estimates of roughly $615.4 million. The company also cited shifting demand for BetterHelp, its mental-health unit, as a major pressure on results. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Teladoc reduced its full-year 2026 revenue outlook to approximately $2.4 billion, below the $2.5 billion consensus. Third-quarter revenue guidance of $569 million to $609 million also fell well short of the roughly $629 million analyst estimate, while the projected quarterly loss is wider than expected. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook

Institutional Trading of Teladoc Health

Several large investors have recently bought and sold shares of TDOC. Dimensional Fund Advisors LP raised its stake in shares of Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares during the period. Trexquant Investment LP acquired a new position in shares of Teladoc Health during the fourth quarter worth $9,156,000. Bridgeway Capital Management LLC purchased a new position in shares of Teladoc Health in the second quarter valued at $8,729,000. Man Group plc boosted its stake in shares of Teladoc Health by 113.8% in the fourth quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock valued at $11,344,000 after purchasing an additional 862,454 shares during the period. Finally, Nuveen LLC grew its holdings in Teladoc Health by 38.7% during the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after purchasing an additional 742,240 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.